Physician profile
Kimberly M Stack
NPI 1366413536
$10,722.67
in general payments reported to CMS, 2019-2025
32 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,263 · 2022: $2,957 · 2023: $1,476 · 2024: $847 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,503.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $4,890.13 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,557.20 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $539.41 | 2021-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $536.29 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $410.69 | 2021-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Axsome Therapeutics, INC. | $402.70 | 2022-2025 | Auvelity |
| Corium, LLC | $348.41 | 2022-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $253.69 | 2021-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $253.08 | 2021-2022 | |
| Novo Nordisk INC | $182.47 | 2024-2025 | Wegovy, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $163.20 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $150.81 | 2024-2025 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $138.12 | 2022-2023 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.49 | 2025 | Xifaxan |
| Lundbeck LLC | $111.67 | 2022-2024 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $107.77 | 2023-2024 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $83.57 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $76.39 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $56.40 | 2025 | Otezla, Repatha |
| Alkermes, INC. | $44.86 | 2022-2023 | Aristada, Lybalvi |
| Exact Sciences Corporation | $43.68 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $32.86 | 2024 | Arexvy, Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $32.85 | 2021-2024 | Fanapt |
| Indivior INC. | $28.99 | 2024 | Sublocade |
| Avanir Pharmaceuticals, INC. | $28.78 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $23.72 | 2025 | |
| Collegium Pharmaceutical, INC. | $22.33 | 2025 | Jornay Pm |
| Astellas Pharma US INC | $21.29 | 2024 | Veozah |
| Almatica Pharma LLC | $16.04 | 2024 | Loreev Xr |
| Alfasigma USA, INC. | $15.82 | 2021 | |
| Tolmar, INC. | $14.85 | 2025 | Jatenzo |
| Jazz Pharmaceuticals INC. | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Stack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.